Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iBioIBIO -1.04%30 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates IBIO with a GF Score™ of 30/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, iBio ranks worse than 142653.21% on this metric.
The historical rank and industry rank for iBio's Days Payable or its related term are showing as below:
During the past 13 years, iBio's highest Days Payable was 716.50. The lowest was 500.94. And the median was 608.72.
IBIO's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
iBio's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
iBio Days Payable Related Terms
iBio Days Payable Historical Data
* Premium members only.
The historical data trend for iBio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, iBio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iBio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, iBio's Days Payable distribution charts can be found below:
* The bar in red indicates where iBio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
iBio's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iBio (IBIO) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on iBio and its competitors. Over the past decade, iBio's Days Payable has ranged from 500.94 to 716.50. According to the industry distribution chart, iBio ranks #999999 out of 701 companies in the Biotechnology industry.
Is iBio's Days Payable too high?
iBio's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 500.94 to a high of 716.50. Based on the distribution chart, iBio ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, iBio has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iBio's Days Payable compare to RNTX and RANI?
According to the Biotechnology industry distribution chart, iBio ranks #999999 out of 701 companies for Days Payable. This places iBio in the lower half of its industry. The industry median Days Payable is 112.84. Historically, iBio's own Days Payable has ranged from 500.94 to 716.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on iBio and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iBio's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iBio stock overvalued right now?
Based on GuruFocus' analysis, iBio (IBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $1.44 — trading 2770% above its estimated fair value. The current Days Payable is 0.00. iBio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For iBio (IBIO), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iBio (IBIO) Overvalued in 2026?
Based on GuruFocus' analysis, iBio stock appears to be overvalued.
The current stock price of $1.44 is trading 2770% above its estimated GF Value™ of $0.05.
GuruFocus considers iBio to be Significantly Overvalued.
Key valuation signals for IBIO:
Days Payable: 0.00
GF Value™: $0.05 vs. price of $1.44 (2770% above fair value)
No single metric tells the full story. See the IBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
30GF Score
Get the complete analysis for IBIO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBIO has been successfully added to your 
